Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

102.17 +1.96 (+1.96%)
Streaming Delayed Price Updated: 2:48 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
Company to host conference call on April 7 at 8 a.m. ET 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
New registry study to focus on impact of fatigue in people with craniopharyngioma 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.